NNovo Nordisk Read More Novo Nordisk Faces Generic Onslaught and Dividend Adjustment in Key Market2026-03-30 Novo Nordisk’s semaglutide patent expires in India, sparking generic price war. Stock hits 52-week low while trading ex-dividend,…
CCopenhagen Read More Copenhagen Airport Flight Disruptions: March 2026 Travel Alert2026-03-28 Copenhagen Airport (CPH) Grapples With Significant Flight Disruptions Copenhagen Airport, one of Northern Europe’s busiest aviation hubs, is…
NNovo Nordisk Read More Novo Nordisk Faces Investor Scrutiny Amid U.S. Pricing Pressure2026-03-26 Novo, Nordisk 26.03.2026 – 06:56:58 | boerse-global.de Novo Nordisk faces revenue pressure from U.S.…
NNovo Nordisk Read More Hims & Hers Faces Profitability Squeeze After Novo Nordisk Settlement2026-03-23 Hims & Hers resolves legal dispute with Novo Nordisk for weight-loss drug rights, but the shift to branded…
NNovo Nordisk Read More Novo Nordisk Faces Swedish Reimbursement Challenge and Shifts US Legal Strategy2026-03-18 Novo Nordisk appeals Sweden’s Wegovy reimbursement denial, withdraws US patent lawsuit. Reports strong 2025 revenue growth but shares…
NNovo Nordisk Read More Novo Nordisk Faces Mounting Pressure as Rival Gains Ground2026-03-08 Novo Nordisk faces intense competition from Eli Lilly in the $100B obesity drug market, with clinical data and…
NNovo Nordisk Read More Novo Nordisk Faces Mounting Competition in Key Diabetes Drug Market2026-03-04 Aspen Pharmacare targets 2026 generic Ozempic launch in Canada after semaglutide patent expiry, pressuring Novo Nordisk amid a…
NNovo Nordisk Read More Novo Nordisk Faces Mounting Challenges on Pricing and Pipeline2026-03-02 Novo Nordisk slashes US prices for Ozempic, Wegovy, and Rybelsus to $675/month in 2027. Its new obesity drug,…
NNovo Nordisk Read More Novo Nordisk Faces Mounting Pressure as Generic Rival Emerges2026-02-17 The Danish pharmaceutical giant’s commanding position in the weight-loss drug market is under significant threat. Novo Nordisk, already…
NNovo Nordisk Read More Novo Nordisk Faces Manufacturing Push and Regulatory Scrutiny2026-02-16 The Danish pharmaceutical giant Novo Nordisk is navigating a complex landscape as it seeks to expand production for…
NNovo Nordisk Read More Novo Nordisk Faces Dual FDA Scrutiny and Legal Battles Over Obesity Drugs2026-02-14 Trump Administration Pushes Back on UN Climate Proposal Global climate diplomacy has entered another tense chapter. The administration…